ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.05 CNY | -0.94% |
|
-0.26% | -12.25% |
| May. 31 | Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024 | CI |
| May. 06 | China Approves Tianyu Pharma's Heart Medication | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 9,134 | 17,038 | 16,825 | 8,880 | 7,555 | 6,476 | - |
| Enterprise Value (EV) 1 | 9,134 | 17,038 | 16,825 | 8,880 | 7,555 | 6,476 | 6,476 |
| P/E ratio | 15.6 x | 25.5 x | 81.9 x | -75.1 x | 271 x | 22.8 x | 21.8 x |
| Yield | - | 0.53% | 0.21% | - | 0.23% | 0.58% | 1.15% |
| Capitalization / Revenue | 4.33 x | 6.58 x | 6.61 x | 3.33 x | 2.99 x | 2.17 x | 1.88 x |
| EV / Revenue | 4.33 x | 6.58 x | 6.61 x | 3.33 x | 2.99 x | 2.17 x | 1.88 x |
| EV / EBITDA | 11.5 x | 18.7 x | 38.8 x | 58 x | 20.6 x | 10.9 x | 12.7 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | 4.48 x | 6.42 x | 4.54 x | 2.54 x | 2.17 x | 1.77 x | 1.63 x |
| Nbr of stocks (in thousands) | 328,031 | 328,002 | 347,977 | 347,977 | 347,977 | 343,927 | - |
| Reference price 2 | 27.84 | 51.94 | 48.35 | 25.52 | 21.71 | 19.05 | 19.05 |
| Announcement Date | 4/23/20 | 4/19/21 | 4/21/22 | 4/26/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,111 | 2,587 | 2,545 | 2,667 | 2,527 | 2,986 | 3,454 |
| EBITDA 1 | 792.6 | 912.5 | 434.1 | 153.1 | 366.1 | 595 | 509 |
| EBIT 1 | 688.3 | 775.7 | 240.1 | -101.8 | 70.75 | 335.5 | 355 |
| Operating Margin | 32.61% | 29.98% | 9.43% | -3.82% | 2.8% | 11.24% | 10.28% |
| Earnings before Tax (EBT) 1 | 684.1 | 768.9 | 218.4 | -110.5 | 71.92 | 334.5 | 353 |
| Net income 1 | 585.7 | 667.1 | 204.7 | -119 | 27.36 | 290.5 | 305.5 |
| Net margin | 27.75% | 25.78% | 8.04% | -4.46% | 1.08% | 9.73% | 8.85% |
| EPS 2 | 1.789 | 2.033 | 0.5900 | -0.3400 | 0.0800 | 0.8350 | 0.8750 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2778 | 0.1000 | - | 0.0500 | 0.1100 | 0.2200 |
| Announcement Date | 4/23/20 | 4/19/21 | 4/21/22 | 4/26/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 S1 |
|---|---|
| Net sales | - |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 68.11 |
| Net margin | - |
| EPS 2 | 0.2000 |
| Dividend per Share | - |
| Announcement Date | 8/28/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 33.7% | 28.5% | 5.65% | -3.29% | 0.78% | 7.9% | 7.65% |
| ROA (Net income/ Total Assets) | - | 17.3% | 3.83% | - | - | 3.9% | 2.7% |
| Assets 1 | - | 3,865 | 5,345 | - | - | 7,449 | 11,315 |
| Book Value Per Share 2 | 6.210 | 8.090 | 10.70 | 10.00 | 10.00 | 10.80 | 11.70 |
| Cash Flow per Share 2 | 1.300 | 1.900 | -0.7500 | -0.1400 | -0.1300 | 0.9200 | 1.380 |
| Capex 1 | 353 | 505 | 736 | 523 | 313 | 103 | 154 |
| Capex / Sales | 16.74% | 19.53% | 28.9% | 19.61% | 12.39% | 3.45% | 4.46% |
| Announcement Date | 4/23/20 | 4/19/21 | 4/21/22 | 4/26/23 | 4/25/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
19.05
CNY
Average target price
22.6
CNY
Spread / Average Target
+18.64%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.25% | 905M | |
| +19.89% | 43.32B | |
| +20.38% | 22.81B | |
| +16.89% | 15.32B | |
| +23.97% | 14.91B | |
| +58.59% | 13.23B | |
| -0.05% | 6.79B | |
| -15.52% | 6.51B | |
| -8.87% | 5.73B | |
| +12.39% | 5.53B |
- Stock Market
- Equities
- 300702 Stock
- Financials Zhejiang Tianyu Pharmaceutical Co., Ltd.
